Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell renal cell carcinoma, alone and in key first-line combinations.
|Videos|September 22, 2020
A 58-Year-Old Man With Advanced Renal Cell Carcinoma
Author(s)Robert Alter, MD
Robert Alter, MD, of John Theurer Cancer Center, describes the rationale for treating a 58-year-old male with advanced renal cell carcinoma with the combination of lenvatinib and everolimus following progression on first-line therapy.
Advertisement
Case: A 58-Year-Old Man With Advanced Renal Cell Carcinoma
- August 2018: A 58-year-old man complained of fatigue and anorexia; after appropriate workup the patient was diagnosed with clear cell renal cell carcinoma
- He underwent left total nephrectomy
- March 2019: He developed metastatic disease to the lungs bilaterally (30 x 35 mm), mediastinum and soft tissue metastatic deposits
- MSKCC risk status: intermediate
- ECOG 1
- He was started on pembrolizumab 200 mg IV every 21 days + axitinib 5 mg PO q2Days
- September 2019: He developed progressive disease (45 x 50 mm); pulmonary lymph nodes increased in size and new mediastinal and hilar lymphadenopathy was noted
- He was started on lenvatinib 18 mg PO qDay + everolimus 5 mg PO qDay
- October 2019: Due to grade 1 diarrhea, reduced dose of lenvatinib to 14 mg PO qDay + everolimus 5 mg PO qDay
- December 2019: Lesions reduced to 20 x 20 mm from September 2019; achieved partial response
- January 2020: He remained on therapy with lenvatinib + everolimus
Advertisement
Related to this article
SABR improved recurrence-free survival vs historical benchmark with IVC tumor thrombus; investigators hypothesize this could be used to reduce invasive surgery.
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
5